Veracyte is evolving from a strong genomic diagnostics franchise into a profitable precision oncology compounder, with dominant guideline-backed tests, expanding margins, a debt-free balance sheet, and major upside tied to Prosigna LDT and TrueMRD adoption.
Overview
Veracyte is a precision diagnostics leader focused on oncology and endocrinology, using genomic sequencing and machine-learning classifiers to reduce diagnostic uncertainty and help patients avoid unnecessary invasive procedures. Revenue is dominated by reimbursed U.S. testing services, supported by product sales from international diagnostic kits and smaller biopharma collaborations. Core tests including Afirma, Decipher, Prosigna, TrueMRD, and Percepta are backed by strong clinical evidence, payer coverage, and guideline recognition. Clinicians choose Veracyte for validated, workflow-integrated molecular insights that improve treatment decisions across thyroid, prostate, bladder, breast, and lung indications.